Author:
Reeve J.,Bradbeer J. N.,Arlot M.,Davies U. M.,Green J. R.,Hampton L.,Edouard C.,Hesp R.,Hulme P.,Ashby J. P.,Zanelli J. M.,Meunier P. J.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism
Reference28 articles.
1. Reeve J, Meunier PJ, Parsons JA et al. The anabolic effect of human parathyroid hormone fragment (hPTH 1–34) therapy on trabecular bone in involutional osteoporosis: Report of a multicentre trial. Br Med J 1980; 280: 1340–4.
2. Hesp R, Hulme P, Williams D, Reeve J. The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human parathyroid hormone fragment (hPTH 1–34). Metab Bone Dis Rel Res 1981; 2: 331–4.
3. Neer RM, Slovik D, Doppelt S et al. The use of parathyroid hormone plus 1,25 dihydroxyvitamin D to increase trabecular bone in oesteoporotic men and postmenopausal women. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis 1987. Copenhagen: Osteopress ApS 1987: 829–35.
4. Reeve J. Davies UM, Hesp R, McNally E, Katz D. Human parathyroid peptide treatment of osteoporosis substantially increases spinal trabecular bone. Br Med J 1990; 301: 314–18 and 477.
5. Reeve J, Arlot ME, Price TR et al. Periodic courses of human 1–34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis. Eur J Clin Invest 1987; 17: 421–8.
Cited by
119 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献